Inhibition of HRG1 binding to its receptor, and ErbB3 activation, with seribantumab, reduced tumor growth in immunocompromised mice bearing patient-derived xenograft (PDX) tumors that expressed high HRG1 levels and an activated HER2/ErbB3 axis. Here, ERBB2 is linked to neoplasm.